Last reviewed · How we verify

NCT04057001: HERCULES

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

Terminated Last updated 25 August 2023
What this trial tests

trial in Liver Transplant; Complications in 49 participants. Terminated before completion.

Timeline
1 July 2019
Primary endpoint
6 March 2023
6 March 2023

Quick facts

Lead sponsorYale University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment49
Start date1 July 2019
Primary completion6 March 2023
Estimated completion6 March 2023
Sites1 location across United States

Conditions studied

Sponsor

Yale University

Who can join

18 and older, any sex, with Liver Transplant; Complications or Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare wait list mortality and time to liver, heart or kidney transplant for registrants listed to consider allografts from Hepatitis C Virus (HCV) Nucleic Amplification Testing (NAT)+ donors versus those who are not . The umbrella protocol has been set up to include heart and kidney transplant recipients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Transplant; Complications

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04057001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing